vs
安进（AMGN）与Smurfit Westrock（SW）财务数据对比。点击上方公司名可切换其他公司
安进的季度营收约是Smurfit Westrock的1.3倍（$9.9B vs $7.6B），安进净利率更高（13.5% vs 1.3%，领先12.2%），安进同比增速更快（8.6% vs 0.5%），安进自由现金流更多（$961.0M vs $612.0M），过去两年Smurfit Westrock的营收复合增速更高（60.8% vs 15.1%）
安进是总部位于美国加利福尼亚州千橡市的跨国生物制药企业，公司名称取自最初的全称「应用分子遗传学」的缩写组合，按营收规模排名位列全球生物医药企业第18位，专注于研发、生产及商业化创新生物药物，为全球患者提供优质治疗选择。
Smurfit Westrock plc是总部位于爱尔兰都柏林的企业，核心业务为生产瓦楞包装及各类纸制包装产品，公司股票同时在纽约证券交易所和伦敦证券交易所挂牌上市。
AMGN vs SW — 直观对比
营收规模更大
AMGN
是对方的1.3倍
$7.6B
营收增速更快
AMGN
高出8.0%
0.5%
净利率更高
AMGN
高出12.2%
1.3%
自由现金流更多
AMGN
多$349.0M
$612.0M
两年增速更快
SW
近两年复合增速
15.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $9.9B | $7.6B |
| 净利润 | $1.3B | $97.0M |
| 毛利率 | 69.8% | 18.2% |
| 营业利润率 | 27.6% | 5.1% |
| 净利率 | 13.5% | 1.3% |
| 营收同比 | 8.6% | 0.5% |
| 净利润同比 | 112.6% | -33.6% |
| 每股收益（稀释后） | $2.45 | $0.18 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMGNSW
| Q4 25 | $9.9B | $7.6B | ||
| Q3 25 | $9.6B | $8.0B | ||
| Q2 25 | $9.2B | $7.9B | ||
| Q1 25 | $8.1B | $7.7B | ||
| Q4 24 | $9.1B | $7.5B | ||
| Q3 24 | $8.5B | $7.7B | ||
| Q2 24 | $8.4B | $3.0B | ||
| Q1 24 | $7.4B | $2.9B |
净利润AMGNSW
| Q4 25 | $1.3B | $97.0M | ||
| Q3 25 | $3.2B | $246.0M | ||
| Q2 25 | $1.4B | $-28.0M | ||
| Q1 25 | $1.7B | $384.0M | ||
| Q4 24 | $627.0M | $146.0M | ||
| Q3 24 | $2.8B | $-150.0M | ||
| Q2 24 | $746.0M | $132.0M | ||
| Q1 24 | $-113.0M | $191.0M |
毛利率AMGNSW
| Q4 25 | 69.8% | 18.2% | ||
| Q3 25 | 67.8% | 19.6% | ||
| Q2 25 | 67.2% | 19.1% | ||
| Q1 25 | 63.6% | 20.6% | ||
| Q4 24 | 65.7% | 19.1% | ||
| Q3 24 | 61.1% | 17.6% | ||
| Q2 24 | 61.4% | 23.3% | ||
| Q1 24 | 57.0% | 24.2% |
营业利润率AMGNSW
| Q4 25 | 27.6% | 5.1% | ||
| Q3 25 | 26.4% | 6.6% | ||
| Q2 25 | 28.9% | 3.2% | ||
| Q1 25 | 14.5% | 7.2% | ||
| Q4 24 | 25.4% | 5.3% | ||
| Q3 24 | 24.1% | 0.7% | ||
| Q2 24 | 22.8% | 8.2% | ||
| Q1 24 | 13.3% | 10.5% |
净利率AMGNSW
| Q4 25 | 13.5% | 1.3% | ||
| Q3 25 | 33.7% | 3.1% | ||
| Q2 25 | 15.6% | -0.4% | ||
| Q1 25 | 21.2% | 5.0% | ||
| Q4 24 | 6.9% | 1.9% | ||
| Q3 24 | 33.3% | -2.0% | ||
| Q2 24 | 8.9% | 4.4% | ||
| Q1 24 | -1.5% | 6.5% |
每股收益（稀释后）AMGNSW
| Q4 25 | $2.45 | $0.18 | ||
| Q3 25 | $5.93 | $0.47 | ||
| Q2 25 | $2.65 | $-0.05 | ||
| Q1 25 | $3.20 | $0.73 | ||
| Q4 24 | $1.17 | $-0.12 | ||
| Q3 24 | $5.22 | $-0.30 | ||
| Q2 24 | $1.38 | $0.51 | ||
| Q1 24 | $-0.21 | $0.73 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $9.1B | $892.0M |
| 总债务越低越好 | $54.6B | $13.4B |
| 股东权益账面价值 | $8.7B | $18.3B |
| 总资产 | $90.6B | $45.2B |
| 负债/权益比越低杠杆越低 | 6.31× | 0.73× |
8季度趋势，按日历期对齐
现金及短期投资AMGNSW
| Q4 25 | $9.1B | $892.0M | ||
| Q3 25 | $9.4B | $851.0M | ||
| Q2 25 | $8.0B | $778.0M | ||
| Q1 25 | $8.8B | $797.0M | ||
| Q4 24 | $12.0B | $855.0M | ||
| Q3 24 | $9.0B | — | ||
| Q2 24 | $9.3B | $26.8K | ||
| Q1 24 | $9.7B | $108 |
总债务AMGNSW
| Q4 25 | $54.6B | $13.4B | ||
| Q3 25 | $54.6B | $13.3B | ||
| Q2 25 | $56.2B | $13.3B | ||
| Q1 25 | $57.4B | $12.9B | ||
| Q4 24 | $60.1B | $12.5B | ||
| Q3 24 | $60.4B | $13.2B | ||
| Q2 24 | $62.6B | — | ||
| Q1 24 | $64.0B | — |
股东权益AMGNSW
| Q4 25 | $8.7B | $18.3B | ||
| Q3 25 | $9.6B | $18.4B | ||
| Q2 25 | $7.4B | $18.3B | ||
| Q1 25 | $6.2B | $17.9B | ||
| Q4 24 | $5.9B | $17.4B | ||
| Q3 24 | $7.5B | $18.0B | ||
| Q2 24 | $5.9B | $14.5K | ||
| Q1 24 | $5.0B | $108 |
总资产AMGNSW
| Q4 25 | $90.6B | $45.2B | ||
| Q3 25 | $90.1B | $45.6B | ||
| Q2 25 | $87.9B | $45.7B | ||
| Q1 25 | $89.4B | $44.6B | ||
| Q4 24 | $91.8B | $43.8B | ||
| Q3 24 | $90.9B | $45.0B | ||
| Q2 24 | $90.9B | $26.8K | ||
| Q1 24 | $93.0B | $108 |
负债/权益比AMGNSW
| Q4 25 | 6.31× | 0.73× | ||
| Q3 25 | 5.67× | 0.72× | ||
| Q2 25 | 7.57× | 0.73× | ||
| Q1 25 | 9.24× | 0.72× | ||
| Q4 24 | 10.23× | 0.72× | ||
| Q3 24 | 8.02× | 0.73× | ||
| Q2 24 | 10.57× | — | ||
| Q1 24 | 12.75× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.6B | $1.2B |
| 自由现金流经营现金流 - 资本支出 | $961.0M | $612.0M |
| 自由现金流率自由现金流/营收 | 9.7% | 8.1% |
| 资本支出强度资本支出/营收 | 6.5% | 7.7% |
| 现金转化率经营现金流/净利润 | 1.20× | 12.32× |
| 过去12个月自由现金流最近4个季度 | $8.1B | $1.2B |
8季度趋势，按日历期对齐
经营现金流AMGNSW
| Q4 25 | $1.6B | $1.2B | ||
| Q3 25 | $4.7B | $1.1B | ||
| Q2 25 | $2.3B | $829.0M | ||
| Q1 25 | $1.4B | $235.0M | ||
| Q4 24 | $4.8B | $781.0M | ||
| Q3 24 | $3.6B | $320.0M | ||
| Q2 24 | $2.5B | $340.0M | ||
| Q1 24 | $689.0M | $42.0M |
自由现金流AMGNSW
| Q4 25 | $961.0M | $612.0M | ||
| Q3 25 | $4.2B | $523.0M | ||
| Q2 25 | $1.9B | $307.0M | ||
| Q1 25 | $980.0M | $-242.0M | ||
| Q4 24 | $4.4B | $212.0M | ||
| Q3 24 | $3.3B | $-192.0M | ||
| Q2 24 | $2.2B | $163.0M | ||
| Q1 24 | $459.0M | $-166.0M |
自由现金流率AMGNSW
| Q4 25 | 9.7% | 8.1% | ||
| Q3 25 | 44.4% | 6.5% | ||
| Q2 25 | 20.8% | 3.9% | ||
| Q1 25 | 12.0% | -3.2% | ||
| Q4 24 | 48.4% | 2.8% | ||
| Q3 24 | 39.0% | -2.5% | ||
| Q2 24 | 26.5% | 5.5% | ||
| Q1 24 | 6.2% | -5.7% |
资本支出强度AMGNSW
| Q4 25 | 6.5% | 7.7% | ||
| Q3 25 | 4.6% | 7.6% | ||
| Q2 25 | 4.0% | 6.6% | ||
| Q1 25 | 5.0% | 6.2% | ||
| Q4 24 | 4.1% | 7.5% | ||
| Q3 24 | 3.0% | 6.7% | ||
| Q2 24 | 2.8% | 6.0% | ||
| Q1 24 | 3.1% | 7.1% |
现金转化率AMGNSW
| Q4 25 | 1.20× | 12.32× | ||
| Q3 25 | 1.46× | 4.61× | ||
| Q2 25 | 1.59× | — | ||
| Q1 25 | 0.80× | 0.61× | ||
| Q4 24 | 7.61× | 5.35× | ||
| Q3 24 | 1.26× | — | ||
| Q2 24 | 3.30× | 2.58× | ||
| Q1 24 | — | 0.22× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMGN
| Products | $9.4B | 95% |
| Xgeva | $291.0M | 3% |
| Vectibix | $163.0M | 2% |
| Aranesp | $115.0M | 1% |
SW
| Packaging | $3.3B | 43% |
| Other | $3.2B | 43% |
| Paper | $1.1B | 14% |
